ClinicalTrials.gov
public full text
Public Domain
Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients
To measure the effect of Ivermectin (sub-cutaneous) with or without zinc in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients#861950
- Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis#967803
- Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial#121353
- Influence of Nutritional Indices on the Prognosis of Patients With SARS-CoV-2 Infection#905113
- Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan#1030148
Record · ID 872159
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive